A serum albumin variant, or functional fragment thereof, comprising, one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).

To provide a pharmaceutical composition having a novel use comprising a dental pulp-derived multipotent stem cell preparation that can be administered to humans. A pharmaceutical composition comprising dental pulp-derived stem cells as an active ingredient for suppressing infiltration into a tissue of at lease neutrophils, monocytes, or lymphocytes.

The present disclosure relates to methods of treating neointimal hyperplasia. The methods include selecting a subject having a blood vessel abnormality, and administering to the subject an amount of a composition, wherein the composition comprises an inhibitor of cell adhesion molecule receptor/Junctional Adhesion Molecule-A (F11R/JAM-A).

Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.

The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.

Methods and materials for effective dosages of AAV gene therapy for the treatment and prophylaxis of hemophilia A.

Methods and materials for effective dosages of AAV gene therapy for the treatment and prophylaxis of hemophilia A.

A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing red cell-derived particles (RCDP) from plasma.

A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing red cell-derived particles (RCDP) from plasma.

Cosmetic compositions are widely used to obtain certain benefits like e.g. anti-aging, skin lightening and moisturizing effect. These benefits are delivered by benefit agents (actives) like e.g. anti-oxidants, hyaluronic acid and resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol. However, these actives have a certain shelf life beyond which they tend to degrade in terms of chemical activity and/or their color stability. The present invention discloses a novel process to prepare cosmetic compositions that improved color stability of resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol and compositions comprising such actives when prepared as per said process.